Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy
Archives of Gynecology and Obstetrics · 2023
DOI: 10.1007/s00404-023-06962-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Gynecology and Obstetrics, 2023. Verfasst von Giuseppe Cimino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cystic Fibrosis Regional Reference Center, A.O.U. Policlinico Umberto I, Rome, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis Transmembrane Conductance Regulator, Cystic Fibrosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Management of cystic fibrosis has recently stepped forward with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, although data on potential adverse effects are lacking for many categories of patients, such as pregnant women. METHODS: We report one of the first reports on the outcome of pregnancy in a woman treated with Elexacaftor/Tezacaftor/Ivacaftor during the second and third trimester of pregnancy, showing a significant improvement of respiratory status, compared with the first trimester when the medication was discontinued due to unknown and, therefore, potential teratogenic effects. Also, we performed the review of the existing literature on the topic. RESULTS: The course of pregnancy was uneventful, with reference to major obstetric complications, and the patient delivered a healthy neonate. These results were similar to those coming from other short series of pregnant women affected by cystic fibrosis and treated with CFTR modulators during pregnancy. CONCLUSIONS: Thus, despite the lack of evidence on the topic, the use of Elexacaftor/Tezacaftor/Ivacaftor in pregnancy seems to be apparently not associated with major adverse events, thus opening optimistic scenarios in terms of management of these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cystic Fibrosis Regional Reference Center, A.O.U. Policlinico Umberto I, Rome, Italy.
- Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Via del Policlinico, 155, 00161, Rome, Italy.
- Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Via del Policlinico, 155, 00161, Rome, Italy. sara.sorrenti@uniroma1.it.
- Emergency and General Pediatrics Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Department of Biology and Biotechnology "C. Darwin", Sapienza University of Rome, Rome, Italy.
- Department of Chemistry and Technology of Drugs, "Department of Excellence 2018-2022", Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Sara Sorrenti
Zitieren
APA
Cimino, G., Sorrenti, S., Murciano, M., Galoppi, P., Ascenzioni, F., Botta, B., Brunelli, R., & Sapienza University Working Group on Cystic Fibrosis in Pregnancy (2023). Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-023-06962-5
Vancouver
Cimino G, Sorrenti S, Murciano M, Galoppi P, Ascenzioni F, Botta B, et al. Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. Archives of Gynecology and Obstetrics. 2023. doi:10.1007/s00404-023-06962-5
BibTeX
@article{Cimino2023,
author = {Cimino, Giuseppe and Sorrenti, Sara and Murciano, Manuel and Galoppi, Paola and Ascenzioni, Fiorentina and Botta, Bruno and Brunelli, Roberto and Sapienza University Working Group on Cystic Fibrosis in Pregnancy, Sapienza University Working Group on Cystic Fibrosis in Pregnancy},
title = {Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy},
journal = {Archives of Gynecology and Obstetrics},
year = {2023},
doi = {10.1007/s00404-023-06962-5}
}
EUVIMED